Detection Of KRAS Gene Mutations In Peripheral Blood And Tumor Tissues Of Patients With Pancreatic Cancer

Objective130peripheral blood and30tumor tissues of pancreatic cancer were detected forKRAS gene mutations by using of HRM,13cases in which matched peripheral bloodand tumor tissues. Meanwhile, we analyzed the relationship between KRAS genemutations and the patients’ sex, age, smoking history, position, size, staging, andpathological types.2To detect the KRAS gene mutation rate in peripheral blood and tumor tissues by HRMin patients with pancreatic cancer, furthermore to compare the consistency of KRASgene mutations, which could be used to explore the feasibility of detection of KRASgene mutations in peripheral blood.It could also provide a KRAS gene detectionmethod that specimen was easy to obtain, dynamic monitoring, non-invasive, and wassuitable for clinical application.3To discuss the sensitivity and feasibility of HRM to detect KRAS mutation inperipheral blood.Methods130peripheral blood,25tumor tissues and5tumor fresh tissues of pancreatic cancerwere collected in July2011to November2012,13cases in which matched peripheral blood and tumor tissue. We detected the KRAS gene mutations rate in peripheral bloodand tumor tissues by HRM in patients with pancreatic cancer, furthermore to analyzethe relationship between KRAS gene mutations and the patients’ clinical feature.2Compared the consistency of KRAS gene mutations in13cases in which matchedperipheral blood and tumor tissue and analyzed the consistency of KRAS genemutations, which helped explore the feasibility of detection of KRAS gene mutations inperipheral blood.Results1The rate and the consistency of KRAS gene mutation of pancreatic cancer patients inperipheral blood and tumor tissuesThere were15cases of30peripheral blood samples which had KRAS gene mutations;the mutation rate was50%.21cases of30tissue specimens had KRAS gene mutation,the mutation rate was70%;5cases were detected KRAS mutations at the same time, inwhich13cases matched peripheal blood and tumor tissue, and the type of KRASmutations detected by direct sequencing were identical completely. The consistency ofKRAS mutations with tumor tissue and peripheal blood reached62.5%(5/8).2The relationship between KRAS gene mutations in peripheral blood and tumor tissueof pancreatic cancer patients and the patients’clinical feature(1)The KRAS gene mutation rate in peripheral blood: male group was52.9%(9/17),female group was46.2%(6/13);≥60years old group was61.1%(11/18),<60yearsold group was33.3%(4/12); smoking group was55.6%(5/9), non-smoking groupwas47.6%(10/21); pancreatic head tumor group was38.1%(8/21), non-pancreatic head tumor group was77.8%(7/9); stage I~II group was52.9%(9/17), stage Ⅲ~Ⅳ groupwas46.2%(6/13).There had no relationship between the KRAS gene mutation inperipheral blood and gender, age, smoking history, tumor location, stage (P>0.05);(2) The KRAS gene mutation rate in tumor tissue: male groups was82.6%(19/23),female group was28.6%(2/7);≥60years old group was66.7%(8/12),<60years oldgroup was72.2%(13/18); smoking group was80%(8/10), non-smoking group (65%13/20); pancreatic head tumor group was76.5%(13/17), non-pancreatic head tumorgroup was61.5%(8/13); stage I~II group was63.6%(14/22), stage Ⅲ~Ⅳgroup was87.5%(7/8); High differentiation group was61.5%(8/13), low differentiation groupwas76.5%(13/17); KRAS mutations of tumor tissue was higher in male than female (P<0.05), but there had no relationship between the KRAS gene mutation and age,smoking history, tumor location, tumor cell differentiation, stage (P>0.05).Conclusion1The mutation rate of KRAS gene of pancreatic cancer in peripheral blood and tumortissues was high. There had no relationship between the KRAS gene mutation inperipheral blood and gender, age, smoking history, tumor location, stage; KRASmutations of tumor tissue was higher in male than female,but there had no relationshipbetween the KRAS gene mutation and age, smoking history, tumor location, tumor celldifferentiation, stage (P>0.05).2It’s sensitive to detect KRAS mutations in peripheral blood by HRM. The consistencyof KRAS gene mutations was high in matched peripheral blood and tumor tissue,whichprovide evidence for peripheral blood instead of tumor tissue to detect KRASmutations.Meanwhile HRM was simple, low-cost, low pollution, suitable for clinical.With feature of easily collected, non-invasive, real-time, dynamic monitoring, and so on, peripheal blood was a better choice for KRAS mutation detection.